Mohammadi Seyed-Farzad, Alinia Cyrus, Tavakkoli Maryam, Lashay Alireza, Chams Hormoz
Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran 1336616351, Iran.
Department of Public Health, School of Public Health, Urmia University of Medical Sciences, Urmia 5756151818, Iran.
Int J Ophthalmol. 2018 Jun 18;11(6):1013-1019. doi: 10.18240/ijo.2018.06.20. eCollection 2018.
To compare the lifetime and annual economic burden of spectacles, contact lenses, and refractive surgery in correction of refractive errors.
This is a cross-sectional study with convenience sampling which 120 patients were interviewed in a tertiary referral hospital in the Iranian health care system. The bottom-up based cost of illness approach was estimated using a face-to-face interview to assess the direct and indirect cost of different refractive errors correction of any correction technologies.
Correction with spectacle imposes a total direct cost of US dollar (US$) 342.5 (±8.41) per year and US$9373.5 (±230.1) per lifetime to each patient. These figures for the contact lenses were obtained US$198.3 (±0.12) and US$5203.1 (±256.3) and for refractive surgery were obtained US$19.1 (±1.2) and US$568.1 (±64.6), respectively. Overall, based on age-adjusted prevalence rates, astigmatism had the highest share of refractive errors economic burden with a lifetime direct cost of slightly less than US$5.49 billion, while hyperopia and myopia imposed less than US$5.24 and 4.2 billion on patients, respectively. The annually imposed cost on each individual Iranian patient with refractive errors is US$308.5.
Based on 18mo post refractive surgery course observation, which is generalized to whole life, refractive surgery significantly imposed much less cost compared with spectacles and contact lenses. Refractive errors among Iranians result in considerable economic burden. Using the refractive surgery instead of other two correction methods has the ability to reduce this economic loss in the future.
比较眼镜、隐形眼镜和屈光手术矫正屈光不正的终生和年度经济负担。
这是一项采用便利抽样的横断面研究,在伊朗医疗保健系统的一家三级转诊医院对120名患者进行了访谈。采用自下而上的疾病成本法,通过面对面访谈估计不同屈光不正矫正技术的直接和间接成本。
每位患者使用眼镜矫正每年的直接成本为342.5美元(±8.41美元),终生成本为9373.5美元(±230.1美元)。隐形眼镜的这些数字分别为198.3美元(±0.12美元)和5203.1美元(±256.3美元),屈光手术的数字分别为19.1美元(±1.2美元)和568.1美元(±64.6美元)。总体而言,根据年龄调整后的患病率,散光在屈光不正经济负担中所占份额最高,终生直接成本略低于54.9亿美元,而远视和近视分别给患者带来的负担不到52.4亿美元和42亿美元。伊朗每位屈光不正患者每年承担的成本为308.5美元。
基于对屈光手术后18个月病程的观察并推广至终生,屈光手术与眼镜和隐形眼镜相比,成本显著低得多。伊朗人的屈光不正造成了相当大的经济负担。未来使用屈光手术而非其他两种矫正方法有能力减少这种经济损失。